Think Bioscience Secures $55M Series A for 'Undruggable' Target Therapies
January 22, 2026, 3:38 am
Location: United States, California, Palo Alto
Employees: 11-50
Founded date: 2010
Think Bioscience, a Boulder, CO-based drug discovery innovator, closed an oversubscribed $55 million Series A funding round. This substantial investment accelerates R&D and operational expansion. The firm pioneers small molecule therapeutics against historically 'undruggable' disease targets. Its unique synthetic biology platform identifies novel binding sites. The lead program focuses on Noonan syndrome, a severe genetic condition with no approved treatments. This funding empowers Think Bioscience to bring groundbreaking therapies to patients facing critical unmet medical needs, reshaping the future of drug development.
Boulder, Colorado’s Think Bioscience has made significant strides. The company secured substantial Series A funding. An oversubscribed $55 million round closed recently. This investment propels its innovative drug discovery mission. Think Bioscience targets conditions previously deemed untreatable. Their focus remains on small molecule drugs. This marks a pivotal moment for advanced therapeutics.
The Series A round was highly competitive. It attracted top-tier investors. Regeneron Ventures led the financing. Innovation Endeavors also played a key role. Janus Henderson Investors joined as a lead. This strong syndicate signals market confidence. Other participants included T.A. Springer. CE-Ventures contributed. MBX Capital and YK Bioventures also invested. Existing backers showed continued support. AV8 Ventures returned. CU Innovations reinforced its commitment. Buff Gold Ventures also reinvested. The collective backing highlights Think Bioscience's potential.
Funds will fuel aggressive expansion. Operations will scale up. Research and development efforts will intensify. The company plans to advance its internal pipeline. New programs will emerge. Existing programs will accelerate. This capital infusion ensures robust growth. It supports the next phase of discovery.
Think Bioscience stands out. It tackles historically "undruggable" targets. These proteins lack easily accessible pockets for drug binding. Conventional methods often fail here. This leaves many diseases without effective treatments. The company employs a unique scientific platform. This platform integrates diverse expertises. Synthetic biology forms its core. Protein biophysics contributes vital insights. Applied enzymology is a key component. Computational chemistry aids design. Medicinal chemistry refines compounds. This multidisciplinary approach yields breakthroughs. The platform identifies unseen "footholds" on proteins. These are novel binding pockets. Such discoveries enable new medicinal chemistry programs. They open avenues previously closed. The company expands the addressable therapeutic landscape. This moves beyond traditional limitations. Think Bioscience offers fresh hope where others falter. Recent advances in computational drug design bolster its capabilities. This pioneering work offers a paradigm shift. It unlocks new frontiers in drug development.
The lead program targets Noonan syndrome. This genetic condition impacts many lives. Approximately 1 in 2,500 births are affected. Patients suffer severe symptoms. Life-threatening cardiac issues are common. Lymphatic complications also arise. Short stature is a frequent trait. Cognitive impairment can occur. Chronic pain also burdens patients. Currently, no approved therapies address the disease's underlying biology. Think Bioscience aims to change this. Their program offers a novel therapeutic path. It seeks to target specific mutants. This could provide meaningful relief. It promises a better quality of life. The need for effective treatment is urgent.
Beyond Noonan syndrome, the platform shows versatility. Think Bioscience applies its technology broadly. It explores a range of target classes. Transcription factors are under investigation. Protein phosphatases are another focus. Kinases, proteases, and GTPases are also targeted. This comprehensive strategy builds a robust pipeline. It demonstrates the platform's power. Diverse diseases could benefit. The company's reach extends far. Its innovative methods unlock new possibilities. This broadens the scope of future therapies.
This significant funding round reinforces Boulder's biotech prominence. It validates Think Bioscience's novel science. The market recognizes the immense value of addressing "undruggable" targets. Such innovation drives industry progress. Investment in early-stage drug discovery remains crucial. Think Bioscience is positioned for leadership in this niche. Its advancements could redefine therapeutic boundaries. The company's journey promises impactful patient solutions. The global biopharmaceutical market seeks transformative therapies. Think Bioscience addresses this critical demand. Its platform offers a distinct competitive edge. The ability to unlock new protein binding sites is a game-changer. This approach accelerates drug discovery timelines. It reduces the risk associated with traditional methods. The potential for first-in-class programs is high. This attracts strong investor interest. The company's success could pave the way for other innovative ventures. It strengthens the entire biotechnology ecosystem.
Think Bioscience charts a new course. It addresses profound medical challenges. The $55 million Series A empowers this mission. Expect further breakthroughs from Boulder. The future of drug discovery holds promise.
Boulder, Colorado’s Think Bioscience has made significant strides. The company secured substantial Series A funding. An oversubscribed $55 million round closed recently. This investment propels its innovative drug discovery mission. Think Bioscience targets conditions previously deemed untreatable. Their focus remains on small molecule drugs. This marks a pivotal moment for advanced therapeutics.
The Series A round was highly competitive. It attracted top-tier investors. Regeneron Ventures led the financing. Innovation Endeavors also played a key role. Janus Henderson Investors joined as a lead. This strong syndicate signals market confidence. Other participants included T.A. Springer. CE-Ventures contributed. MBX Capital and YK Bioventures also invested. Existing backers showed continued support. AV8 Ventures returned. CU Innovations reinforced its commitment. Buff Gold Ventures also reinvested. The collective backing highlights Think Bioscience's potential.
Funds will fuel aggressive expansion. Operations will scale up. Research and development efforts will intensify. The company plans to advance its internal pipeline. New programs will emerge. Existing programs will accelerate. This capital infusion ensures robust growth. It supports the next phase of discovery.
Think Bioscience stands out. It tackles historically "undruggable" targets. These proteins lack easily accessible pockets for drug binding. Conventional methods often fail here. This leaves many diseases without effective treatments. The company employs a unique scientific platform. This platform integrates diverse expertises. Synthetic biology forms its core. Protein biophysics contributes vital insights. Applied enzymology is a key component. Computational chemistry aids design. Medicinal chemistry refines compounds. This multidisciplinary approach yields breakthroughs. The platform identifies unseen "footholds" on proteins. These are novel binding pockets. Such discoveries enable new medicinal chemistry programs. They open avenues previously closed. The company expands the addressable therapeutic landscape. This moves beyond traditional limitations. Think Bioscience offers fresh hope where others falter. Recent advances in computational drug design bolster its capabilities. This pioneering work offers a paradigm shift. It unlocks new frontiers in drug development.
The lead program targets Noonan syndrome. This genetic condition impacts many lives. Approximately 1 in 2,500 births are affected. Patients suffer severe symptoms. Life-threatening cardiac issues are common. Lymphatic complications also arise. Short stature is a frequent trait. Cognitive impairment can occur. Chronic pain also burdens patients. Currently, no approved therapies address the disease's underlying biology. Think Bioscience aims to change this. Their program offers a novel therapeutic path. It seeks to target specific mutants. This could provide meaningful relief. It promises a better quality of life. The need for effective treatment is urgent.
Beyond Noonan syndrome, the platform shows versatility. Think Bioscience applies its technology broadly. It explores a range of target classes. Transcription factors are under investigation. Protein phosphatases are another focus. Kinases, proteases, and GTPases are also targeted. This comprehensive strategy builds a robust pipeline. It demonstrates the platform's power. Diverse diseases could benefit. The company's reach extends far. Its innovative methods unlock new possibilities. This broadens the scope of future therapies.
This significant funding round reinforces Boulder's biotech prominence. It validates Think Bioscience's novel science. The market recognizes the immense value of addressing "undruggable" targets. Such innovation drives industry progress. Investment in early-stage drug discovery remains crucial. Think Bioscience is positioned for leadership in this niche. Its advancements could redefine therapeutic boundaries. The company's journey promises impactful patient solutions. The global biopharmaceutical market seeks transformative therapies. Think Bioscience addresses this critical demand. Its platform offers a distinct competitive edge. The ability to unlock new protein binding sites is a game-changer. This approach accelerates drug discovery timelines. It reduces the risk associated with traditional methods. The potential for first-in-class programs is high. This attracts strong investor interest. The company's success could pave the way for other innovative ventures. It strengthens the entire biotechnology ecosystem.
Think Bioscience charts a new course. It addresses profound medical challenges. The $55 million Series A empowers this mission. Expect further breakthroughs from Boulder. The future of drug discovery holds promise.